Lots of interesting abstracts and cases were submitted for TCTAP 2023. Below are the accepted ones after a thorough review by our official reviewers. Don’t miss the opportunity to expand your knowledge and interact with authors as well as virtual participants by sharing your opinion in the comment section!
TCTAP A-082
Novel CHA2DS2-VASc-HSF as a Predictor In-Stent Restenosis in Coronary Artery Disease Patient After Stent Implantation
By Ronaldi Rizkiawan, Ivana Purnama Dewi, Louisa Fadjri Kusuma Wardhani, I Gde Rurus Suryawan, Andrianto Andrianto
Presenter
Ronaldi Rizkiawan
Authors
Ronaldi Rizkiawan1, Ivana Purnama Dewi2, Louisa Fadjri Kusuma Wardhani1, I Gde Rurus Suryawan3, Andrianto Andrianto1
Affiliation
Dr. Soetomo General Hospital, Indonesia1, Duta Wacana Christian University, Indonesia2, Dr. Soetomo Academic General Hospital, Indonesia3
View Study Report
TCTAP A-082
Others (Unclassified)
Novel CHA2DS2-VASc-HSF as a Predictor In-Stent Restenosis in Coronary Artery Disease Patient After Stent Implantation
Ronaldi Rizkiawan1, Ivana Purnama Dewi2, Louisa Fadjri Kusuma Wardhani1, I Gde Rurus Suryawan3, Andrianto Andrianto1
Dr. Soetomo General Hospital, Indonesia1, Duta Wacana Christian University, Indonesia2, Dr. Soetomo Academic General Hospital, Indonesia3
Background
In-stent restenosis (ISR) is a limitation of percutaneous coronary intervention that has been connected to various clinical and angiographic factors. To date, drug-eluting stents (DES) have significantly reduced the ISR rate. Some prediction models have been developed to considerably reduce ISR incidents. This study aims to assess the prognostic value of Gensini, CHA2DS2-VASc, and CHA2DS2-VASc-HSF scores on ISR in patients who had DES implantation for coronary heart disease (CAD).
Methods
We have done a retrospective study for all patients who underwent DES implantations at Integrated Cardiac Care Center, Dr. Soetomo Hospital, Surabaya, Indonesia, between January 2020 and October 2022. ISR was defined as a diameter stenosis of ≥50% within a coronary stent. Demographic, clinical data and angiographic characteristics were collected to calculate Gensini, CHA2DS2-VASc, and CHA2DS2-VASc-HSF scores. Statistical analyses were done using MedCalc 18.2.1. and SPSS 25.0.
Results
We enrolled total 335 patients (mean age 58.56 ± 10.92 years and 81.2% were men) who underwent angiography and DES implantation. The patients were divided into 2 groups; ISR (n = 89) and non-ISR (n = 246). The mean CHA2DS2-VASc and CHA2DS2-VASc-HSF scores were higher for ISR group (3.31 ± 1.25 vs 2.65 ± 1.07; p < 0.001 and 4.99 ± 1.19 vs 3.75 ± 1.08; p < 0.001, respectively). From ROC curve, it is shown that CHA2DS2-VASc-HSF score has highest area under the curve (AUC) compared to Gensini and CHA2DS2-VASc score (AUC 0.78, 95% CI 0.727–0.842; p < 0.001).
Conclusion
CHA2DS2-VASc-HSF score has better ability to predict ISR compared to Gensini score and CHA2DS2-VASc score. Thus, this score can be used as a simple and effective tool to predict ISR in patients undergoing DES implantation.